After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...